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ABSTRACT
Background: Women with a history of hypertensive disorders of pregnancy (HDP) are at 
increased long-term risk of cardiovascular disease. However, there has been increasing 
evidence on the same risks in the months following birth. 
Objectives: This review aims to estimate the incidence of hypertension in the first two 
years after HDP.
Search Strategy: MEDLINE, EMBASE and Cochrane databases were systematically 
searched in October 2019.
Selection Criteria: Observational studies comparing hypertension rate following HDP 
and normotensive pregnancies up to two years. 
Data Collection and Analysis: A meta-analysis to calculate the odds ratio (OR) with a 
95% confidence interval (CI) and a sub-group analysis excluding women with chronic 
hypertension were performed.
Main Results: Hypertension was diagnosed within the first two years following 
pregnancy in 468/1646 (28.4%) and 584/6395 (9.1%) of the HDP and control groups, 
respectively (OR=6.28; 95% CI 4.18-9.43; I2=56%). The risk of hypertension in HDP 
group was significantly higher in the first six months following delivery (OR=18.33; 95% 
CI 1.35-249.48; I2=84%) than at six to twelve months (OR=4.36; 95% CI 2.81-6.76; 
I2=56%) or between one to two years postpartum (OR 7.24; 95% CI 4.44-11.80; I2=9%). 
A sub-group analysis demonstrated a similar increase in the risk of developing 
postpartum hypertension after HDP (OR 5.75; 95% CI 3.92–8.44; I2=49%) and 
preeclampsia (OR=6.83; 95% CI 4.25-10.96; I2=53%).
Conclusions: The augmented risk of hypertension after HDP is highest in the early 
postpartum period suggesting that diagnosis and targeted interventions to improve 
maternal cardiovascular health may need to be commenced in the immediate postpartum 
period. 
Funding: the iPLACENTA project (grant agreement No 765274)
Keywords: preeclampsia, pregnancy and postpartum, hypertension, cardiovascular 
disease prevention, meta-analysis
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Tweetable abstract
The risk of hypertension within two years of birth is six-fold higher in women who 
experienced preeclampsia. 
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INTRODUCTION 
Hypertensive disorders of pregnancy (HDP) that include preeclampsia, eclampsia, 
HELLP syndrome and gestational hypertension affect about 10% of pregnancies and 
have a deleterious effect on future maternal cardiovascular outcomes. Women with a 
history of HDP have an increased risk of coronary artery disease, cerebrovascular 
disease, peripheral arterial disease, and cardiovascular-related mortality to such an 
extent that preeclampsia and gestational hypertension were included by the American 
Heart Association among major risk factors for cardiovascular disease1-3. The augmented 
risk of cardiovascular disease is mainly due to the fact that women develop essential 
hypertension in the years following an HDP index pregnancy4, 5. In addition, the risk of 
developing hypertension and other cardiovascular disorders is higher in women with 
recurrent HDP than those with a single episode of HDP6, 7. Therefore, early diagnosis and 
targeted intervention of hypertension may play a key role in improving future 
cardiovascular health in women with a previous pregnancy affected by HDP. 
The risk of developing cardiovascular disorders after HDP has been mostly assessed by 
large cohort studies examined several decades after delivery. In one meta-analysis which 
included about 3 million women between 1960 and 2006, the estimated relative risk (95% 
confidence intervals) of hypertension after preeclampsia was 3.70 (2.70-5.05) after 14 
years mean follow-up8. However, more recent evidence on the timing of hypertension 
following HDP pregnancy, has suggested that women may develop hypertension within 
months or few years after giving birth. A register-based cohort study on 1.5 million 
primiparas demonstrated that the rate of antihypertensive medication use within one year 
of a HDP pregnancy was higher compared to normotensive pregnancy (11% versus 
0.5%, respectively)4. In a smaller prospective cohort study of 200 women one year after 
severe preeclampsia, 41.5% of women had hypertension presenting as either sustained 
hypertension (14.5%), masked hypertension (17.5%), or hypertension only in a clinical 
setting (9.5%) 9. These observations are corroborated by the findings that asymptomatic 
moderate-severe cardiac dysfunction/hypertrophy was observed more frequently in 
preterm preeclampsia (56%) compared to term preeclampsia (14%) or matched controls 
(8%)10.
Elucidating the temporal pattern and magnitude of hypertension after a pregnancy 
affected by HDP would help to design and deliver cardiovascular disease preventive A
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strategies after HDP. The aim of this study is to review and analyse the available 
literature reporting the incidence of hypertension in the first two years after HDP 
compared to uncomplicated pregnancy. 
MATERIALS AND METHODS
Protocol, eligibility criteria, information sources and search
This review was performed according to a priori designed protocol recommended for 
systematic review and meta-analysis11. MEDLINE, EMBASE and Cochrane Library 
databases were searched electronically in October 2019, utilizing combinations of the 
relevant medical subject heading (MeSH) terms, key words, and word variants for 
“preeclampsia”, “hypertensive disorders of pregnancy”, “essential hypertension”, and 
“postpartum period” (Appendix S1). The search and selection criteria were restricted to 
human studies. No time and language restrictions were applied. Conference abstract, 
case reports, letters and editorials were excluded. Reference lists of relevant articles and 
reviews were hand searched for additional reports. PRISMA and MOOSE guideline were 
followed12-14. The study was registered with the PROSPERO database (Registration 
number: CRD42019149123).
Study selection, data collection and data items
The primary outcome was to assess the incidence of hypertension after pregnancies 
complicated by HDP that include preeclampsia, eclampsia, HELLP syndrome and 
gestational hypertension within two years postpartum. We included case-control and 
cohort studies that presented data on how many patients suffer from hypertension from 
six weeks up to two years postpartum. The whole time period was divided into three 
groups: up to six months, six months to one year, one year to two years.  Hypertension 
was defined when systolic blood pressure (SBP) 140 mm Hg and/or diastolic blood 
pressure (DBP)  90 mm Hg occurs more than one occasion in a clinical setting15. The 
use of antihypertensive medication and lower approved cut-offs to define hypertension 
were also included as diagnostic criteria16. When data were available, only cases 
affected by preeclampsia were considered in the analysis. We excluded studies where 
chronic hypertension defined as pre-existing the index pregnancy or developing before 
20 weeks were not clearly defined. If a study included patients with chronic hypertension, A
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we considered only articles that provided the number of patients affected by chronic 
hypertension. Moreover, we did not include articles with incidence rate and cumulative 
incidence of postpartum hypertension after HDP beyond two years postpartum. 
All abstract screening was performed independently by two researchers (VG, AR). Then, 
the full text of those potentially eligible studies was retrieved and independently assessed 
for eligibility by the two researchers (VG, AR). Any inconsistency and disagreement were 
discussed with a third reviewer (EK) and a consensus was reached. Few articles in 
language other than English were translated to decide whether they would be suitable or 
not for inclusion. A reviewer (VG) extracted data regarding study characteristics and 
outcomes, in particular author, year, location, study type, population size, inclusion 
criteria, exclusion criteria, reported outcomes, blood pressure assessment method and 
setting, hypertension definition and time of measurement. If more than one study was 
published for the same cohort with equal endpoints, the report containing the most 
comprehensive information on the population was included to avoid overlapping 
populations.  For those articles in which information was not reported but the 
methodology showed that this information would have been recorded initially, the authors 
were contacted.
Patients were not involved in the development of this study and a core outcome set was 
not used. 
Quality assessment of the included studies was performed using the Newcastle-Ottawa 
Scale (NOS) for cohort and case-control studies. According to NOS, each study was 
judged on three broad perspectives: the selection of the study groups, the comparability 
of the groups, and the ascertainment of outcome of interest or exposure. Assessment of 
the selection of a study includes the evaluation of the representativeness of the exposed 
cohort, selection of the non-exposed cohort, ascertainment of exposure and the 
demonstration that the outcome of interest was not present at the start of study. 
Assessment of the comparability of the study includes the evaluation of the comparability 
of groups based on the design or analysis. Finally, while the ascertainment of the 
outcome of interest includes the evaluation of the type of the assessment of the outcome 
of interest, length and adequacy of follow-up, the ascertainment of the exposure includes 
the evaluation of the type of the assessment of the exposure for cases and controls and 
the non-response rates. According to NOS a study can be awarded a maximum of one A
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star for each numbered item within the Selection and Outcome/Exposure categories. A 
maximum of two stars can be given for Comparability17.
The overall quality of evidence for the outcome was assessed using Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) system that 
rates fields, namely, risk of bias, inconsistency, indirectness, imprecision, publication 
bias, large effect, plausible confounding and dose response gradient in order to obtain 
different categories for the quality of a body of evidence (high, moderate, low, very low). 
This reflects the degree of confidence of how near our estimate of the effect lies to the 
true effect and the level of confidence decreases with decreasing quality18, 19.
Statistical analysis
The risk of hypertension after HDP and uncomplicated pregnancy was calculated pooling 
respectively events and cases of all studies. The tables including raw outcome data were 
used to calculate the overall combined odds ratio (OR) with its 95% confidence interval 
(CI). In order to obtain a more precise risk estimate of postpartum hypertension in women 
with HDP during their pregnancy a meta-analysis was performed using a random effects 
model because of the high level of heterogeneity among the selected studies. The 
significance of the combined OR calculated using the Mantel-Haenszel statistical method 
was determined by the Z test and the p-value. A continuity correction technique was used 
to handle zero count cells in the tables. The variance between the studies was tested 
using the I2 statistics. The I2 index expresses the percentage of the total variation across 
studies that are due to heterogeneity. I2 values of 25, 50 and 75% correspond to low, 
moderate and high heterogeneity, respectively. Meta-regression was carried out using 
mixed-effects model. Sub-analyses were planned for factors significantly contributing to 
the statistical heterogeneity. Since the number of included studies was adequate, the 
publication bias was explored with funnel plots asymmetry tests. Statistical analyses were 
performed using R for statistical computing software. 
RESULTS
General characteristics
15 studies were included in the systematic review after assessing 223 articles in full-text 
with respect to their eligibility for inclusion from the 8407 articles identified through the A
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search (Figure 1, Table S1, Table S2)10, 20-33. Among these studies, 14/15 were cohort 
studies and 1/15 was a case-control. The total population sample size ranged from 28 to 
5105 patients and follow-up from 2 to 24 months postpartum. Four studies included 
women with chronic hypertension pre-existing the index pregnancy22, 23, 26, 30, and 3 out of 
4 provided the outcome data without these cases22, 23, 30. In 11 studies the authors 
reported the technique of blood pressure measurement. In 4 out of 11, hypertension was 
diagnosed using a standard sphygmomanometer10, 20, 25, 33, and in 7 out of 11 an 
automatic device was employed21, 22, 24, 27, 28, 31, 32. In addition, in one study the incidence 
of hypertension was self-reported by patients by using a standardized questionnaire23. 
The cut-off of SBP/DBP to define hypertension in an office setting was defined in 12 
studies and it was 140/90 mmHg in 10/12 studies10, 20, 22, 24, 25, 27, 28, 30-33, 130/80 in one 
study25 and 120/80 in another study21. Table S2 showed that women with a history of 
HDP were more likely to have a higher body mass index than controls in 7 studies10, 21, 22, 
26, 29, 30, 33 (46.7%) and to be older than controls in 5 studies21, 23, 26, 29, 33 (33.3%). The 
number of early-onset preeclampsia was reported by four papers23, 26, 32, 33, whereas 
those of HDP that required delivery before 37 weeks were described in other four 
studies10, 20, 24, 27. 
Synthesis of the results
Overall, 1646 women with a history of HDP were compared to 6395 women with a 
previous uneventful pregnancy (Figure 2).  The total number of women who developed 
hypertension in the first two years was 468/1646 (28.4%) and 584/6395 (9.1%) in the 
HDP and control group, respectively (OR=6.28; 95% CI 4.18-9.43; I2=56%). The OR of 
postpartum hypertension in HDP group was 18.33 (95% CI 1.35-249.48; I2=84%) in the 
period up to six months, 4.36 (95% CI 2.81-6.76; I2=56%) in the period from six to one 
year and 7.24 (95% CI 4.44-11.80; I2=9%) between one year and two years. Data on 
preeclampsia were reported by 13 studies and Figure S1 shows the comparisons of the 
postpartum incidence of hypertension between women affected by preeclampsia and 
controls. In the pooled analysis an increased risk of hypertension was observed for 
preeclampsia (OR=7.49; 95% CI 4.58-12.26). Heterogeneity among the studies was 
moderate (I2 = 60%). The same trend of HDP has been observed in the different time 
periods up to two years (up to six months OR=57.08; 95% CI 11.00-296.07; six months to A
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one year OR=4.83; 95% CI 2.78-8.37; one year to 2 years OR=7.44; 95% CI 4.19-13.21). 
The heterogeneity was 0%, 58% and 20% in up to six months, six months to one year 
and one year to two years, respectively. In both meta-analyses, heterogeneity was 
explained to some extent (45.3% and 36.9%, respectively) by the incidence of chronic 
hypertension as showed by meta-regression (p= 0.034 and 0.092, for HDP and PE 
model, respectively). Therefore, a sub-group analysis excluding this population was 
conducted.
Sub-group analysis
14 studies were eligible to perform the subgroup analysis because they excluded women 
with pre-existing hypertension in calculating the outcome. Among them, data on 
preeclampsia were reported by 12 studies. Pooled results of studies excluding 
hypertension before the index pregnancy reported an overall OR of 5.75 (95% CI 3.92–
8.44; I2=49%) for the risk of developing postpartum hypertension in women with a history 
of HDP compared to women without (Figure 3). The OR is reported at 13.39 (95% CI 
1.27-141.04; I2=72%), 4.13 (95% CI 2.82-6.07; I2=54%), 8.73 (95% CI 4.66-16.35; 
I2=23%) in the period up to six months, between six months and one year and between 
one and two years, respectively. Considering only data on preeclampsia, women with a 
pregnancy complicated by preeclampsia were at a significantly increased risk of 
postpartum hypertension than women with normotensive pregnancy (OR=6.83, 95% CI 
4.25-10.96; I2=53%) with the following discrepancies among the different periods: up to 
six months OR=43.95 (95% CI 5.72-338.04; I2=0%), six months to one year OR=4.46 
(95% CI 2.76-7.21; I2= 56%), one year to two years OR=8.91 (95% CI 4.33-18.33; I2= 
33%) (Figure S2). 
Publication bias, study quality and quality of evidence
No evidence of publication bias has been detected in studies including women with 
pregnancies affected by HDP (p=0.890) or preeclampsia (p=0.666), as illustrated by 
funnel plots (Figures S3 and S4). The NOS quality scores were high among 5 of the 15 
studies with a NOS score of 8 (Table S1). The meanSD overall score for all 15 studies 
was 6.91.0. The quality of evidence, according to GRADE, was calculated for the 
incidence of hypertension after HDP and after preeclampsia. In the former analysis, it A
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was low for the results obtained up to six months and from six month to one year and it 
was moderate for the incidence of hypertension assessed between one to two years 
(Table S3). In the latter analysis, the quality of evidence was moderate in the first and in 
the last period and low between six months and one year (Table S4). The low/moderate 
quality of evidence was mainly because any study design other than randomized 
controlled trials carries a high risk of bias. The difference in the quality of evidence 
among different periods was due to the magnitude of association and the impact of the 
‘risk of bias’ and/or ‘inconsistency’ parameters (Tables S3 and S4).
DISCUSSION
Main findings
The risk of developing hypertension within two years in women with a history of HDP is 
six-fold higher compared to women after normotensive pregnancy. A subgroup analysis 
of studies where pre-existing hypertension was excluded, revealed that there is a similar 
overall OR and trend for developing hypertension in the three postpartum periods 
analysed, with the risk being more than 10-fold in the first six months, 4-fold at six months 
to one year and 8-fold at one to two years.
Strengths and limitations
This systematic review enlightens the magnitude of the risk of developing hypertension 
within the first two years after delivery in women who experienced HDP in the index 
pregnancy by a comprehensive review and analysis of the current literature. We included 
study where HDP were precisely defined and where women with chronic hypertension 
were excluded or defined clearly. However, the current study has some limitations to be 
considered. First, the quality assessment of the studies showed that only five studies 
reached a score equal or more than 8. Furthermore, the quality of evidence is low or 
moderate according to GRADE, therefore, caution is needed when interpreting the 
results. For instance, only around one third of the studies reported a significantly higher 
maternal age in women with a history of HDP than in controls. This could be due to a 
selection bias of the control group, in particular in the smaller studies, and it might explain 
why the control group had a relative high risk of hypertension (9.1%). A
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Second, the risk of hypertension was highest in the immediate postpartum period (< six 
months), however, it might be due to an overestimation of the risk because of the paucity 
of studies in this time period or to a delayed resolution of pregnancy hypertension. 
However, Behrens et al.4 also described the highest risk of developing hypertension in 
the year after delivery compared to the following years after excluding prescription of any 
antihypertensive drug that could be related to a treatment for HDP (i.e. use of 
antihypertensive from 20 weeks of gestation up to three months postpartum). Another 
aspect to be addressed regarding the immediate postpartum is when the follow-up should 
be started after delivery. We included studies reporting outcomes past six weeks 
postpartum, but we acknowledge that literature regarding the time when preeclampsia 
resolves is unclear. Guidelines reported 6 weeks or three months as the point where 
normalization of blood pressure after preeclampsia would be expected34, 35. Thus, current 
evidence from published literature is not enough to define the best screening period in 
the postpartum to detect hypertension. Third, heterogeneity in population and in 
hypertension definition in addition to the failure of obtaining sufficient details could make 
results of the meta-analysis misleading and impossible to be adjusted by using statistical 
tests. 
Interpretation
This review quantifies the risk of hypertension in the immediate postpartum period after a 
pregnancy complicated by HDP, highlighting the importance of early diagnosis and 
intervention for hypertension in this period. These results are consistent with growing 
evidence on the association between HDP and cardiovascular diseases, but prior 
research and meta-analysis were focused on the long-term consequences rather than 
those soon after delivery8, 36. The results of studies with more immediate cardiovascular 
follow-up after delivery (and the current meta-analysis) provide more reliable data on the 
development of cardiovascular diseases after delivery. The Nurses’ Health Study II 
demonstrated that women who reported a first pregnancy affected by HDP presented 
higher rates of hypertension (HR 2.8; 95% CI 2.6-3.0), type 2 diabetes mellitus (HR 1.7; 
95% CI 1.4-1.9), and hypercholesterolemia (HR 1.4; 95% CI 1.3-1.5) within five years 
postpartum37. A recent prospective observational cohort that followed 4484 women for 
mean 3.2 years after their first pregnancy showed that women with any hypertensive A
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disorder of pregnancy had higher adjusted risk of hypertension at follow-up compared 
with controls (RR 2.7; 95% CI 2.0-3.6)38. Moreover, a register-based study showed that 
women with HDP had twice the risk of cardiovascular readmissions (acute myocardial 
infarction, stroke or heart failure) within three years compared to normal pregnancies39. 
One case-control study (n=142) demonstrated an elevated risk of hypertension at two 
years following delivery for women with preeclampsia10. Lastly, a large Danish register-
based cohort study with a ten-year follow-up revealed that rates of persistent 
hypertension were 12-fold to 25-fold higher in the first year after delivery and 4-fold to 10-
fold higher between one and five years in women with a hypertensive disorder of 
pregnancy than in women with a normotensive pregnancy4.
The temporal shift from decades to early postpartum years in maternal cardiovascular 
care highlights the need to bridge the gap between obstetric care and adult preventive 
medicine40. First of all, an awareness campaign about the significance of a history of 
pregnancy complications should be focused on family practitioners and cardiovascular 
specialists. Secondly, given the earlier risk of developing hypertension in women after 
HDP, serial blood pressure monitoring should be scheduled in the first months to years 
following birth. It would appear useful to evaluate blood pressure measurements at 8-12 
weeks postpartum and again within two years of the index HDP pregnancy. If 
hypertension is diagnosed, lifestyle changes, medical therapy and standard follow-up 
should be highly encouraged (Figure 4). To support such proposals, a prospective blood 
pressure screening trial should be conducted to understand the optimal regimen for 
monitoring blood pressure after previous HDP.
This systematic review shows that there is a paucity of research in the first months after 
delivery compared to the following years. This research should be focused on developing 
effective screening, follow-up and targeted intervention strategies for women after 
preeclampsia despite presenting a unique opportunity for early intervention. In particular, 
no research has investigated how to identify subjects at increased risk of cardiovascular 
diseases among women with HDP or preeclampsia in the peripartum period. Some 
cardiac functional abnormalities, such as diastolic dysfunction, left ventricular remodeling 
and reduced left ventricular contractility in the peripartum period might be unique markers 
in order to identify women at higher risk of future cardiovascular diseases.A
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Conclusion
This systematic review defines the risk of developing hypertension in the first two years 
after a hypertensive pregnancy and highlights the window of opportunity for 
cardiovascular prevention in women with a diagnosis of hypertension after delivery.  
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FIGURE LEGENDS
Figure 1. PRISMA Flow Diagram
Figure 2. The incidence of hypertension after hypertensive disorders of pregnancy (HDP) 
up to two years postpartum
Figure 3. The incidence of hypertension after hypertensive disorders of pregnancy (HDP) 
up to two years postpartum (excluding cases with chronic hypertension).
Figure 4. Flow-chart for cardiovascular system evaluation after hypertensive disorders of 
pregnancy.
HDP hypertensive disorders of pregnancy, BP blood pressure, CVS cardiovascular 
system, HT hypertension, ACC/AHA American College of Cardiology/American Heart 
Association
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